Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 44 entries
Sorted by: Best Match Show Resources per page
CHEK2 1100 delC mutation in Russian ovarian cancer patients.

Hereditary cancer in clinical practice

Krylova NY, Ponomariova DN, Sherina NY, Ogorodnikova NY, Logvinov DA, Porhanova NV, Lobeiko OS, Urmancheyeva AF, Maximov SY, Togo AV, Suspitsin EN, Imyanitov EN.
PMID: 19725991
Hered Cancer Clin Pract. 2007 Sep 15;5(3):153-6. doi: 10.1186/1897-4287-5-3-153.

BRCA1 and BRCA2 germ-line mutations occur in a significant number of unselected ovarian cancer (OC) patients, thus making a noticeable contribution to OC morbidity. It is of interest whether CHEK2, which is frequently regarded as a third breast cancer...

Unusual Clinical Presentation of Gastrointestinal Clear Cell Sarcoma.

Gastrointestinal tumors

Raskin GA, Pozharisski KM, Iyevleva AG, Rikov IV, Orlova RV, Imyanitov EN.
PMID: 26675070
Gastrointest Tumors. 2015 Sep;2(2):83-8. doi: 10.1159/000430881. Epub 2015 May 29.

BACKGROUND: Use of molecular assays is gradually becoming a mandatory part of the clinical management of soft tissue tumors, however the choice and the interpretation of these tests may present a challenge.SUMMARY: This report demonstrates an unusual presentation of...

Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab.

Case reports in oncology

Orlov SV, Urtenova MA, Sviridenko MA, Nesterov DV, Sokolova TN, Imyanitov EN.
PMID: 32999660
Case Rep Oncol. 2020 Aug 19;13(2):985-989. doi: 10.1159/000509241. eCollection 2020.

Activating RAS mutations occur in more than a half of colorectal cancers (CRCs). RAS-mutated CRCs are notoriously difficult to treat given that they are characterized by the aggressive disease course and the lack of appropriate targeted therapies. Recent preclinical...

Molecular tests for prediction of tumor sensitivity to cytotoxic drugs.

Cancer letters

Imyanitov EN, Iyevleva AG.
PMID: 34808283
Cancer Lett. 2022 Feb 01;526:41-52. doi: 10.1016/j.canlet.2021.11.021. Epub 2021 Nov 20.

Chemotherapy constitutes the backbone of cancer treatment. Several predictive assays assist personalized administration of cytotoxic drugs and are recommended for use in a clinical setting. The deficiency of DNA repair by homologous recombination (HRD), which is caused by inactivation...

Molecular tests for prediction of tumor sensitivity to cytotoxic drugs.

Cancer letters

Imyanitov EN, Iyevleva AG.
PMID: 34808283
Cancer Lett. 2021 Nov 20;526:41-52. doi: 10.1016/j.canlet.2021.11.021. Epub 2021 Nov 20.

Chemotherapy constitutes the backbone of cancer treatment. Several predictive assays assist personalized administration of cytotoxic drugs and are recommended for use in a clinical setting. The deficiency of DNA repair by homologous recombination (HRD), which is caused by inactivation...

Cytotoxic and targeted therapy for hereditary cancers.

Hereditary cancer in clinical practice

Iyevleva AG, Imyanitov EN.
PMID: 27555886
Hered Cancer Clin Pract. 2016 Aug 23;14(1):17. doi: 10.1186/s13053-016-0057-2. eCollection 2016.

There is a number of drugs demonstrating specific activity towards hereditary cancers. For example, tumors in BRCA1/2 mutation carriers usually arise via somatic inactivation of the remaining BRCA allele, which makes them particularly sensitive to platinum-based drugs, PARP inhibitors...

Aberrant COL11A1 splicing causes prelingual autosomal dominant nonsyndromic hearing loss in the DFNA37 locus.

Human mutation

Rad A, Schade-Mann T, Gamerdinger P, Yanus GA, Schulte B, Müller M, Imyanitov EN, Biskup S, Löwenheim H, Tropitzsch A, Vona B.
PMID: 33169910
Hum Mutat. 2021 Jan;42(1):25-30. doi: 10.1002/humu.24136. Epub 2020 Nov 11.

Alpha-chain collagen molecules encoded by genes that include COL11A1 are essential for skeletal, ocular, and auditory function. COL11A1 variants have been reported in syndromes involving these organ systems. However, a description of the complete clinical spectrum is lacking, as...

Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

European journal of human genetics : EJHG

Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeney LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubiński J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons MT, Pathak H, Pedersen IS, Peixoto A, Pejovic T, Perez-Segura P, Permuth JB, Peshkin B, Peterlongo P, Piskorz A, Prokofyeva D, Radice P, Rantala J, Riggan MJ, Risch HA, Rodriguez-Antona C, Ross E, Rossing MA, Runnebaum I, Sandler DP, Santamariña M, Soucy P, Schmutzler RK, Setiawan VW, Shan K, Sieh W, Simard J, Singer CF, Sokolenko AP, Song H, Southey MC, Steed H, Stoppa-Lyonnet D, Sutphen R, Swerdlow AJ, Tan YY, Teixeira MR, Teo SH, Terry KL, Terry MB, Thomassen M, Thompson PJ, Thomsen LCV, Thull DL, Tischkowitz M, Titus L, Toland AE, Torres D, Trabert B, Travis R, Tung N, Tworoger SS, Valen E, van Altena AM, van der Hout AH, Van Nieuwenhuysen E, van Rensburg EJ, Vega A, Edwards DV, Vierkant RA, Wang F, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, White E, Whittemore AS, Winham SJ, Wolk A, Woo YL, Wu AH, Yan L, Yannoukakos D, Zavaglia KM, Zheng W, Ziogas A, Zorn KK, Kleibl Z, Easton D, Lawrenson K, DeFazio A, Sellers TA, Ramus SJ, Pearce CL, Monteiro AN, Cunningham J, Goode EL, Schildkraut JM, Berchuck A, Chenevix-Trench G, Gayther SA, Antoniou AC, Pharoah PDP.
PMID: 35027648
Eur J Hum Genet. 2022 Jan 14; doi: 10.1038/s41431-021-00987-7. Epub 2022 Jan 14.

Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented...

Integration of the blood test into the low-dose computed tomography lung cancer screening: reliable discrimination between malignant and non-malignant radiographic findings.

Translational lung cancer research

Kuligina ES, Iyevleva AG, Imyanitov EN.
PMID: 34858791
Transl Lung Cancer Res. 2021 Oct;10(10):4035-4038. doi: 10.21037/tlcr-21-680.

No abstract available.

Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors.

World journal of clinical oncology

Imyanitov E, Sokolenko A.
PMID: 34367927
World J Clin Oncol. 2021 Jul 24;12(7):544-556. doi: 10.5306/wjco.v12.i7.544.

Molecular pathogenesis of tumors arising in

Molecular tests for prediction of tumor sensitivity to cytotoxic drugs.

Cancer letters

Imyanitov EN, Iyevleva AG.
PMID: 34808283
Cancer Lett. 2022 Feb 01;526:41-52. doi: 10.1016/j.canlet.2021.11.021. Epub 2021 Nov 20.

Chemotherapy constitutes the backbone of cancer treatment. Several predictive assays assist personalized administration of cytotoxic drugs and are recommended for use in a clinical setting. The deficiency of DNA repair by homologous recombination (HRD), which is caused by inactivation...

Molecular tests for prediction of tumor sensitivity to cytotoxic drugs.

Cancer letters

Imyanitov EN, Iyevleva AG.
PMID: 34808283
Cancer Lett. 2021 Nov 20;526:41-52. doi: 10.1016/j.canlet.2021.11.021. Epub 2021 Nov 20.

Chemotherapy constitutes the backbone of cancer treatment. Several predictive assays assist personalized administration of cytotoxic drugs and are recommended for use in a clinical setting. The deficiency of DNA repair by homologous recombination (HRD), which is caused by inactivation...

Showing 13 to 24 of 44 entries